8-K: Notable Labs Presents Promising Data on Cryopreserved Samples at AACR 2024, Expanding Predictive Medicine Platform Potential

Notable Labs presented data at AACR 2024 demonstrating the successful use of cryopreserved samples in their Predictive Precision Medicine Platform (PPMP), potentially broadening its application.

Summary

• Notable Labs presented data at the American Association for Cancer Research (AACR) 2024 conference showcasing the successful use of cryopreserved samples in their Predictive Precision Medicine Platform (PPMP).
• The study demonstrated that cryopreserved samples can be effectively used in the PPMP assay, which was previously thought to be challenging due to low sample viability and cell recovery.
• The company adapted an existing methodology to process cryopreserved patient-derived leukemia cells, comparing results with fresh samples.
• The results showed a strong correlation (R2 from 0.77 to 0.92) for venetoclax and 5-azacytidine between fresh and frozen samples.
• The PPMP also correctly predicted clinical responders and non-responders in a biobank of AML patients treated with chemotherapy.
• This innovation expands the potential of the PPMP to assess new treatment regimens, including combination therapies, using archived samples.

Sentiment

Score: 8

Explanation: The document presents positive results from a study that expands the potential of the company's platform. The company is also moving forward with a Phase 2 program. However, there are risks associated with clinical development and funding.

Positives

• The successful use of cryopreserved samples in the PPMP assay expands the platform's potential and applicability.
• The strong correlation between fresh and frozen sample results validates the methodology.
• The PPMP's ability to predict clinical responses using cryopreserved samples opens new opportunities for retrospective studies.
• The company is actively innovating and expanding the reach of its PPMP platform.
• The company is preparing to initiate a Phase 2 program with volasertib in Q2 2024.

Risks

• The company faces risks associated with the clinical development and regulatory approval of product candidates.
• There are risks related to the company's ability to obtain sufficient additional capital.
• The company faces uncertainties in obtaining successful clinical results and unexpected costs.
• There are risks related to the failure to realize any value from product candidates and preclinical programs.
• The company's future financial and operating results are uncertain, including its ability to become profitable.
• The company faces risks related to retaining key personnel and managing the requirements of being a public company.
• The Israel-Hamas war presents uncertainties for the company.
• The company faces risks related to obtaining regulatory approval for its drug candidates.

Future Outlook

The company aims to expand the reach of its PPMP across diseases and predicted medical outcomes, and partner with biopharmaceutical companies to provide new treatment options for patients with cancer. They are also preparing to initiate a Phase 2 program with volasertib in Q2 2024.

Management Comments

• Thomas Bock, M.D., Chief Executive Officer of Notable, stated that the ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important innovation.
• Joseph Wagner, Ph.D., Chief Scientific Officer of Notable, added that the careful evaluation of sample handling protocols makes their PPMP more comprehensive and enhances the opportunity to study and apply it more broadly.

Industry Context

This announcement is significant as it demonstrates an advancement in the use of cryopreserved samples for drug response prediction, which could have broad implications for the pharmaceutical industry and personalized medicine. It positions Notable Labs as a leader in predictive precision medicine.

Comparison to Industry Standards

• The use of cryopreserved samples in drug sensitivity assays is not a standard practice due to challenges with cell viability and recovery, making Notable's achievement a notable advancement.
• Other companies in the precision oncology space, such as Foundation Medicine and Guardant Health, focus on genomic profiling, while Notable's PPMP focuses on functional drug response prediction, offering a different approach.
• The R2 values of 0.77 to 0.92 for correlation between fresh and frozen samples are considered strong, indicating a high level of reliability in the methodology.
• The ability to predict clinical responders and non-responders using cryopreserved samples is a significant step forward compared to traditional methods that rely on fresh samples.

Stakeholder Impact

• Shareholders may view this positively as it expands the potential of the company's platform.
• Employees may be motivated by the company's innovation and progress.
• Customers (biopharmaceutical companies) may be interested in partnering with Notable to utilize their PPMP.
• Patients may benefit from the development of new treatment options.

Next Steps

• Notable will continue to evaluate and validate these sample handling methodologies.
• The full poster will be posted to the company's website.
• The company is preparing to initiate a Phase 2 program with volasertib in Q2 2024.

Key Dates

Keywords

Predictive Precision Medicine Platform, Cryopreserved Samples, AACR 2024, Acute Myeloid Leukemia, PPMP, Oncology, Cancer Therapies, Clinical Trials, Volasertib